Keywords: Actelion, Macitentan, Ph III, PAH, Pulmonary arterial hypertension

Actelion's macitentan meets primary endpoint in pivotal Phase III PAH study

Article | 01 May 2012

Print This

Europe’s largest biotech company, Actelion (SIX: ATLN), says that initial analysis indicates that the pivotal, long-term, event-driven study ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in